scholarly journals Update on the Management of Gastroenteropancreatic Neuroendocrine Tumors With Emphasis on the Role of Imaging

2013 ◽  
Vol 201 (4) ◽  
pp. 811-824 ◽  
Author(s):  
Kyung Won Kim ◽  
Katherine M. Krajewski ◽  
Mizuki Nishino ◽  
Jyothi P. Jagannathan ◽  
Atul B. Shinagare ◽  
...  
2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 376-376
Author(s):  
Rachel M Lee ◽  
Danielle K DePalo ◽  
Alexandra G Lopez-Aguiar ◽  
Mohammad Yahya Zaidi ◽  
Flavio G. Rocha ◽  
...  

376 Background: The prognostic value of pathologic variables is not consistent for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We previously demonstrated a limited prognostic role of lymph node (LN) positivity in small bowel NETs (SBNET) compared to pancreatic NETs (panNET). Although minority race is often associated with worse cancer outcomes, the interaction of race with pathologic and oncologic outcomes of pts with GEP-NETS is not known. Methods: Pts with GEP-NETs who underwent curative intent resection at eight institutions of the US NET Study Group from 2000-16 were included. Given few pts of other races, only Black and White race pts were analyzed. Results: Of 2,182 pts, 1,143 met inclusion criteria. Median age was 58 yrs, median follow up was 3 yrs, 48% were male, 14% (n = 157) were Black, and 86% (n = 986) were White. Black pts were more likely uninsured (7 vs 2%, p = 0.005), had symptomatic bleeding (13 vs 7%, p = 0.006), required emergency surgery (7 vs 3%, p = 0.003), and had LN positive disease (47 vs 36%, p = 0.016). Despite this, Black pts had improved 5 yr recurrence free survival (RFS) compared to White pts (90 vs 80%, p = 0.008). The quality of care received was comparable between both groups, demonstrated by similar LN yield at surgery, neg margin resection rate, post-op complications, and need for reoperation or readmission (all p > 0.05). Black pts were more likely to have SBNET (22 vs 13%) and less likely to have panNET (43 vs 68%) compared to White pts (p < 0.001). Consistent with prior data, pts with LN pos panNET had decreased 5yr RFS (67 vs 83%, p = 0.001); however, for SBNET, LN involvement was not prognostic (77 vs 96%, p = 0.08). The prognostic value of LN pos disease was similar between Black and White pts in both SBNET (p = 0.34) and panNET (p = 0.95). Conclusions: Black pts with GEP-NET present with more advanced disease, including higher LN positivity. Despite this, Black pts have improved RFS compared to White pts. Although there may be delays in seeking or reaching care, Black pts received similar quality of care compared to White pts. The improved RFS seen in Black pts may be attributed to the epidemiologic differences in the site of presentation of GEP-NETs and variable prognostic value of LN pos disease.


2017 ◽  
Vol 2 ◽  
pp. 115-122 ◽  
Author(s):  
Beata Kos-Kudła ◽  
Jarosław Ćwikła ◽  
Marek Ruchała ◽  
Alicja Hubalewska-Dydejczyk ◽  
Barbara Jarzab ◽  
...  

2014 ◽  
Vol 99 (2) ◽  
pp. 75-84 ◽  
Author(s):  
Maja Cigrovski Berkovic ◽  
Tamara Cacev ◽  
Tina Catela Ivkovic ◽  
Vanja Zjacic-Rotkvic ◽  
Sanja Kapitanovic

2006 ◽  
Vol 4 (12) ◽  
pp. 89-90
Author(s):  
P. Grabowski ◽  
J. Schrader ◽  
D. Hörsch ◽  
C.N. Arnold ◽  
H. Stein ◽  
...  

2013 ◽  
Vol 47 (1) ◽  
pp. 54-60
Author(s):  
Vishal Sharma ◽  
Surinder Singh Rana ◽  
Deepak Kumar Bhasin

ABSTRACT The gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare tumors and include all tumors arising from the gastrointestinal (GI) or pancreatic neuroendocrine cells. They can occur anywhere in the GI tract with the small intestine, pancreas and rectum being the common GI sites. Because of nonspecific symptoms they are difficult to diagnose and diagnosis is often delayed by years. Advancement in cross-sectional imaging techniques and advent of radionuclide-labeled somatostatin analogs have improved our accuracy of diagnosis and staging GEP NETs. Endoscopic ultrasound (EUS) with its unique combination of endoscopy and ultrasound provides high resolution images of GI tract wall as well as the surrounding solid parenchymal organs and therefore is an important investigation for the diagnosis and staging of GEP NETs. Surgery is the treatment of choice with good long-term results in patients with localized GEP-NETs. Control of symptoms in functional NETs is warranted to improve the quality of life of the patient. Somatostatin and its analogs like octreotide and lanreotide have been used to control symptoms because of functional NETs. The management of metastatic GEP NETs includes control of symptoms and therapy to decrease/stop tumor growth that includes somatostatin and its analogs and chemotherapy. Newer therapeutic modalities like peptide receptor radionuclide therapy (PRRT) and molecular therapy hold considerable promise. How to cite this article Rana SS, Sharma V, Bhasin DK. Role of Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors and Update on Their Treatment. J Postgrad Med Edu Res 2013;47(1):54-60.


Sign in / Sign up

Export Citation Format

Share Document